Home › Companies › ORIC Pharmaceuticals, Inc. › 2025-2026

ORIC Pharmaceuticals, Inc. 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings and ORIC Pharmaceuticals, Inc.’s Form 8-K, filed 2026-06-22 (Item 5.07 on EDGAR). Page generated 02 October 2026.

8Reported items
189Asset managers
1,586Fund votes
2026-06-18Meeting date

Proxy season: 2025-2026

Explore ORIC Pharmaceuticals, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by ORIC Pharmaceuticals, Inc.

These tallies are ORIC Pharmaceuticals, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-06-22 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

ORIC Pharmaceuticals, Inc. — official shareholder meeting results, meeting held 2026-06-18
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Jacob M. Chacko, M.D.	89,298,150	--	--	408,106	4,865,025	Majority: yes
Elect Director: Mardi C. Dier	82,007,899	--	--	7,698,357	4,865,025	Majority: yes
Proposal 2 - Ratification of Appointment of Independent Registered Public Accounting Firm The Company's stockholders ratified the appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year end	94,536,096	34,641	544	--	0	Majority: yes
Proposal 3 - Approval of the ORIC Pharmaceuticals, Inc. 2020 Equity Incentive Plan, as Amended and Restated The Company's stockholders approved the ORIC Pharmaceuticals, Inc.	61,228,918	27,264,875	1,212,463	--	4,865,025	Majority: yes
Proposal 4 - Advisory Vote to Approve the Compensation of the Company's Named Executive Officers The Company's stockholders approved, on an advisory (non-binding) basis, executive compensation.	88,453,809	1,250,074	2,373	--	4,865,025	Majority: yes
Proposal 5 - Advisory Vote on the Frequency of Future Stockholder Advisory Votes on the Compensation of the Company's Named Executive Officers The Company's stockholders approved, on an advisory (non-binding) basis, for the frequency of fut	89,392,979	--	11,375	--	4,865,025	Outcome not stated

Source: ORIC Pharmaceuticals, Inc., Form 8-K, filed with the SEC on 2026-06-22 — read the filing on EDGAR.

How asset managers voted at the ORIC Pharmaceuticals, Inc. 2025-2026 meeting

Each item below shows how the 189 asset managers that disclosed a ORIC Pharmaceuticals, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of ORIC Pharmaceuticals, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. TO APPROVE, ON AN ADVISORY BASIS, THE FREQUENCY OF FUTURE ADVISORY VOTES ON EXECUTIVE COMPENSATION.

SECTION 14A SAY-ON-PAY VOTESOutcome not stated

Combines 5 wordings of this item as funds reported it.

— Outcome not stated · no against or withheld count reported

ORIC Pharmaceuticals, Inc.’s own tally for this item (“Proposal 5 - Advisory Vote on the Frequency of Future Stockholder Advisory Votes on the Compensation of the Company's Named Executive Officers The Company's stockholders approved, on an advisory (non-binding) basis, for ”): 89,392,979 for; no against or withheld count reported, per its Form 8-K filed 2026-06-22 (Item 5.07).

The 186 asset managers below cast 99.9% of the shares they voted on this item FOR (15,609,045 for, 73 against).

FOR 17%ONE YEAR 58%1 YEAR 25%

FOR: 15,609,045 (16.9%)AGAINST: 73 (0.0%)ONE YEAR: 53,380,802 (57.7%)1 YEAR: 22,693,441 (24.5%)1-YEAR: 689,023 (0.7%)THREE YEARS: 190,831 (0.2%)3 YEARS: 19,453 (0.0%)1.0: 156 (0.0%)

Largest asset managers voting on “TO APPROVE, ON AN ADVISORY BASIS, THE FREQUENCY OF FUTURE ADVISORY VOTES ON EXECUTIVE COMPENSATION.” at ORIC Pharmaceuticals, Inc., 2025-2026
Asset manager	For	Vote
T. Rowe Price	0	One Year
Nextech Invest Ltd.	0	1 Year
EcoR1 Capital, LLC	6,728,116	For
VIKING GLOBAL INVESTORS LP	0	One Year
Vanguard	0	One Year
SR ONE CAPITAL MANAGEMENT, LP	4,615,384	For
Venrock Adviser, LLC	0	One Year
NEA Management Company, LLC	0	One Year
Fidelity	0	One Year
PFIZER INC	0	1 Year
Column Group LLC	3,540,777	For
BlackRock	0	1 Year
State Street	0	One Year
ORBIMED ADVISORS LLC	0	1 Year
ACAP Strategic Fund	0	One Year
Siren, L.L.C.	0	1 Year
Vivo Capital, LLC	0	One Year
FRANKLIN ADVISERS INC	0	One Year
GEODE CAPITAL MANAGEMENT, LLC	0	One Year
Victory Capital	0	One Year
Charles Schwab	0	1 Year
Royce	0	One Year
Citadel	0	One Year
MUTUAL FUND SERIES TRUST	0	One Year
Candriam S.C.A.	0	One Year

Showing the 25 largest of 186 asset managers. See all 186 in the interactive database.

2. TO APPROVE, ON AN ADVISORY BASIS, EXECUTIVE COMPENSATION.

SECTION 14A SAY-ON-PAY VOTES

98% fund support · no official result

FOR 98%

The 176 asset managers below cast 98% of the shares they voted on this item FOR (79,741,479 for, 1,272,759 against).

FOR: 79,741,479 (98.4%)AGAINST: 1,272,759 (1.6%)

Largest asset managers voting on “TO APPROVE, ON AN ADVISORY BASIS, EXECUTIVE COMPENSATION.” at ORIC Pharmaceuticals, Inc., 2025-2026
Asset manager	For	Against	Vote
T. Rowe Price	9,686,596	0	For
Nextech Invest Ltd.	7,162,637	0	For
VIKING GLOBAL INVESTORS LP	5,824,533	0	For
Vanguard	4,805,274	2	For
Venrock Adviser, LLC	4,319,765	0	For
NEA Management Company, LLC	4,118,621	0	For
Fidelity	3,676,189	0	For
PFIZER INC	3,656,440	0	For
Column Group LLC	3,540,777	0	For
BlackRock	3,421,826	13,135	For
State Street	2,447,867	1,372	For
ORBIMED ADVISORS LLC	2,236,003	0	For
ACAP Strategic Fund	2,226,067	0	For
Siren, L.L.C.	1,990,617	0	For
Vivo Capital, LLC	1,848,786	0	For
FRANKLIN ADVISERS INC	1,827,743	0	For
GEODE CAPITAL MANAGEMENT, LLC	1,675,479	0	For
Victory Capital	1,486,130	0	For
Charles Schwab	1,211,948	0	For
Royce	1,207,223	0	For
Citadel	1,193,696	0	For
MUTUAL FUND SERIES TRUST	951,433	0	For
Candriam S.C.A.	0	823,269	Against
FRANKLIN STRATEGIC SERIES	659,005	0	For
Advantage Advisers Xanthus Fund, L.L.C.	645,814	0	For

Showing the 25 largest of 176 asset managers. See all 176 in the interactive database.

3. TO APPROVE THE ORIC PHARMACEUTICALS, INC. 2020 EQUITY INCENTIVE PLAN, AS AMENDED AND RESTATED.

COMPENSATIONMajority of the votes cast: yes

69% Majority: yes · of votes cast

FOR 69%AGAINST 31%

FOR: 61,228,918AGAINST: 27,264,875

ORIC Pharmaceuticals, Inc.’s own tally for this item (“Proposal 3 - Approval of the ORIC Pharmaceuticals, Inc. 2020 Equity Incentive Plan, as Amended and Restated The Company's stockholders approved the ORIC Pharmaceuticals, Inc.”): 61,228,918 for, 27,264,875 against, per its Form 8-K filed 2026-06-22 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 103,486,412 outstanding shares: 59% for, 26% against (86% of the company cast a for/against vote).

The 61 asset managers below cast 38% of the shares they voted on this item FOR (9,508,974 for, 15,833,496 against).

FOR 36%AGAINST 60%

FOR: 9,508,974 (35.8%)AGAINST: 15,833,496 (59.7%)ABSTAIN: 1,196,702 (4.5%)

Largest asset managers voting on “TO APPROVE THE ORIC PHARMACEUTICALS, INC. 2020 EQUITY INCENTIVE PLAN, AS AMENDED AND RESTATED.” at ORIC Pharmaceuticals, Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
Vanguard	5,523	4,212,194	3	Against
T. Rowe Price	0	4,180,023	0	Against
NEA Management Company, LLC	4,118,621	0	0	For
ACAP Strategic Fund	2,226,067	0	0	For
Fidelity	0	1,981,593	0	Against
State Street	653	1,485,676	0	Against
Royce	0	0	1,196,699	Abstain
BlackRock	0	1,028,647	0	Against
MUTUAL FUND SERIES TRUST	951,433	0	0	For
Victory Capital	0	723,500	0	Against
FRANKLIN STRATEGIC SERIES	659,005	0	0	For
Advantage Advisers Xanthus Fund, L.L.C.	645,814	0	0	For
Charles Schwab	0	605,953	0	Against
Integral Health Asset Management, LLC	561,862	0	0	For
Equitable	0	170,882	0	Against
American Century	0	150,114	0	Against
TIAA	0	144,685	0	Against
Goldman Sachs	127,607	0	0	For
MERIDIAN FUND INC	0	124,858	0	Against
QUANTITATIVE MASTER SERIES LLC	0	104,008	0	Against
JPMorgan	97,916	0	0	For
Brighthouse	138	94,195	0	Against
Lincoln Financial	9,105	73,125	0	Against
Transamerica	0	80,390	0	Against
Dimensional	0	71,943	0	Against

Showing the 25 largest of 61 asset managers. See all 61 in the interactive database.

4. To elect the two Class III directors named in the accompanying proxy statement to serve until the 2029 annual meeting of stockholders or until their successors are duly elected and qualified or until their earlier death, resignation or removal: Jacob M. Chacko, M.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

99.5% Majority: yes · of votes cast

FOR 99.5%

FOR: 89,298,150WITHHELD: 408,106

ORIC Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Jacob M. Chacko, M.D.”): 89,298,150 for, 408,106 withheld, per its Form 8-K filed 2026-06-22 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 103,486,412 outstanding shares: 86% for, 0.4% withheld (87% of the company cast a for/withheld vote).

The 59 asset managers below cast 100% of the shares they voted on this item FOR (21,750,080 for, 0 against).

FOR 99.4%

FOR: 21,750,080 (99.5%)ABSTAIN: 114,925 (0.5%)

Largest asset managers voting on “To elect the two Class III directors named in the accompanying proxy statement to serve until the 2029 annual ” at ORIC Pharmaceuticals, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	4,211,024	6,695	For
T. Rowe Price	4,180,023	0	For
ACAP Strategic Fund	2,226,067	0	For
Fidelity	1,981,593	0	For
State Street	1,484,430	1,899	For
Royce	1,196,699	0	For
BlackRock	1,028,647	0	For
MUTUAL FUND SERIES TRUST	951,433	0	For
Victory Capital	723,500	0	For
FRANKLIN STRATEGIC SERIES	659,005	0	For
Advantage Advisers Xanthus Fund, L.L.C.	645,814	0	For
Charles Schwab	605,953	0	For
Equitable	170,882	0	For
American Century	150,114	0	For
TIAA	144,685	0	For
Goldman Sachs	127,607	0	For
MERIDIAN FUND INC	124,858	0	For
QUANTITATIVE MASTER SERIES LLC	104,008	0	For
JPMorgan	97,916	0	For
Brighthouse	94,333	0	For
Lincoln Financial	80,401	1,829	For
Transamerica	80,390	0	For
Dimensional	0	71,943	Abstain
Russell Investments	71,032	0	For
ProShares	63,853	0	For

Showing the 25 largest of 59 asset managers. See all 59 in the interactive database.

5. To elect the two Class III directors named in the accompanying proxy statement to serve until the 2029 annual meeting of stockholders or until their successors are duly elected and qualified or until their earlier death, resignation or removal: Mardi C. Dier

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

91% Majority: yes · of votes cast

FOR 91%9%

FOR: 82,007,899WITHHELD: 7,698,357

ORIC Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Mardi C. Dier”): 82,007,899 for, 7,698,357 withheld, per its Form 8-K filed 2026-06-22 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 103,486,412 outstanding shares: 79% for, 7% withheld (87% of the company cast a for/withheld vote).

The 59 asset managers below cast 100% of the shares they voted on this item FOR (17,600,116 for, 0 against).

FOR 80%ABSTAIN 20%

FOR: 17,600,116 (80.5%)ABSTAIN: 4,264,889 (19.5%)

Largest asset managers voting on “To elect the two Class III directors named in the accompanying proxy statement to serve until the 2029 annual ” at ORIC Pharmaceuticals, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	4,207,724	9,994	For
T. Rowe Price	4,180,023	0	For
ACAP Strategic Fund	0	2,226,067	Abstain
Fidelity	1,981,593	0	For
State Street	1,482,710	3,619	For
Royce	1,196,699	0	For
BlackRock	1,028,647	0	For
MUTUAL FUND SERIES TRUST	951,433	0	For
Victory Capital	0	723,500	Abstain
FRANKLIN STRATEGIC SERIES	659,005	0	For
Advantage Advisers Xanthus Fund, L.L.C.	0	645,814	Abstain
Charles Schwab	605,953	0	For
Equitable	130,852	40,030	For
American Century	0	150,114	Abstain
TIAA	144,685	0	For
Goldman Sachs	127,607	0	For
MERIDIAN FUND INC	124,858	0	For
QUANTITATIVE MASTER SERIES LLC	104,008	0	For
JPMorgan	97,916	0	For
Brighthouse	72,048	22,285	For
Lincoln Financial	49,905	32,325	For
Transamerica	80,390	0	For
Dimensional	0	71,943	Abstain
Russell Investments	71,032	0	For
ProShares	0	63,853	Abstain

Showing the 25 largest of 59 asset managers. See all 59 in the interactive database.

6. TO RATIFY THE APPOINTMENT OF KPMG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR OUR FISCAL YEAR ENDING DECEMBER 31, 2026.

AUDIT-RELATEDMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

FOR 99.9%

FOR: 94,536,096AGAINST: 34,641

ORIC Pharmaceuticals, Inc.’s own tally for this item (“Proposal 2 - Ratification of Appointment of Independent Registered Public Accounting Firm The Company's stockholders ratified the appointment of KPMG LLP as the Company's independent registered public accounting firm for”): 94,536,096 for, 34,641 against, per its Form 8-K filed 2026-06-22 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 103,486,412 outstanding shares: 91% for, 0.1% against (91% of the company cast a for/against vote).

The 59 asset managers below cast 99.9% of the shares they voted on this item FOR (21,864,946 for, 59 against).

FOR 99.9%

FOR: 21,864,946 (100.0%)AGAINST: 59 (0.0%)

Largest asset managers voting on “TO RATIFY THE APPOINTMENT OF KPMG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR OUR FISCAL YEAR” at ORIC Pharmaceuticals, Inc., 2025-2026
Asset manager	For	Against	Vote
Vanguard	4,217,719	0	For
T. Rowe Price	4,180,023	0	For
ACAP Strategic Fund	2,226,067	0	For
Fidelity	1,981,593	0	For
State Street	1,486,270	59	For
Royce	1,196,699	0	For
BlackRock	1,028,647	0	For
MUTUAL FUND SERIES TRUST	951,433	0	For
Victory Capital	723,500	0	For
FRANKLIN STRATEGIC SERIES	659,005	0	For
Advantage Advisers Xanthus Fund, L.L.C.	645,814	0	For
Charles Schwab	605,953	0	For
Equitable	170,882	0	For
American Century	150,114	0	For
TIAA	144,685	0	For
Goldman Sachs	127,607	0	For
MERIDIAN FUND INC	124,858	0	For
QUANTITATIVE MASTER SERIES LLC	104,008	0	For
JPMorgan	97,916	0	For
Brighthouse	94,333	0	For
Lincoln Financial	82,230	0	For
Transamerica	80,390	0	For
Dimensional	71,943	0	For
Russell Investments	71,032	0	For
ProShares	63,853	0	For

Showing the 25 largest of 59 asset managers. See all 59 in the interactive database.

7. Advisory Vote to Ratify Named Executive Officers' Compensation

COMPENSATION

99.9% fund support · no official result

FOR 99.9%

The 8 asset managers below cast 99.9% of the shares they voted on this item FOR (6,971,798 for, 73 against).

FOR: 6,971,798 (100.0%)AGAINST: 73 (0.0%)

Largest asset managers voting on “Advisory Vote to Ratify Named Executive Officers' Compensation” at ORIC Pharmaceuticals, Inc., 2025-2026
Asset manager	For	Against	Vote
EcoR1 Capital, LLC	6,728,116	0	For
Blue Owl Capital Holdings LP	225,000	0	For
Rhumbline	8,687	73	For
CLEARWATER INVESTMENT TRUST	8,551	0	For
ANTIPODES PARTNERS Ltd	1,278	0	For
ALGERT GLOBAL LLC	161	0	For
Janney Montgomery Scott LLC	5	0	For
Abu Dhabi Investment Council Co P.J.S.C	0	0	--

8. Advisory Vote to Approve the Compensation of our Named Executive Officers

SECTION 14A SAY-ON-PAY VOTES

100% fund support · no official result

FOR 100%

The 2 asset managers below cast 100% of the shares they voted on this item FOR (4,636,254 for, 0 against).

FOR: 4,636,254 (100.0%)

Largest asset managers voting on “Advisory Vote to Approve the Compensation of our Named Executive Officers” at ORIC Pharmaceuticals, Inc., 2025-2026
Asset manager	For	Against	Abstain	Withheld	Vote
SR ONE CAPITAL MANAGEMENT, LP	4,615,384	0	0	0	For
Jasper Ridge Partners, L.P.	20,870	0	0	0	For

Largest ORIC Pharmaceuticals, Inc. shareholders voting in 2025-2026

Ranked by the number of ORIC Pharmaceuticals, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 103,486,412 shares outstanding at the time of that meeting.

Top ORIC Pharmaceuticals, Inc. shareholders by shares voted, 2025-2026
#	Asset manager	% of shares outstanding
1	T. Rowe Price	9.36%
2	Nextech Invest Ltd.	6.92%
3	EcoR1 Capital, LLC	6.50%
4	VIKING GLOBAL INVESTORS LP	5.63%
5	Vanguard	4.64%
6	SR ONE CAPITAL MANAGEMENT, LP	4.46%
7	Venrock Adviser, LLC	4.17%
8	NEA Management Company, LLC	3.98%
9	Fidelity	3.55%
10	PFIZER INC	3.53%

Reported ORIC Pharmaceuticals, Inc. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

ORIC Pharmaceuticals, Inc. beneficial owners on record for the 2025-2026 proxy season
Holder	% outstanding	Disclosure
Entities affiliated with Viking Global Investors	9.32%	DEF14A
VIKING GLOBAL INVESTORS LP	7.99%	13G
Entities affiliated with Nextech Crossover LP	6.92%	DEF14A
Entities affiliated with EcoR1 Capital, LLC	6.50%	DEF14A
BlackRock	5.78%	13F
Entities affiliated with Venrock Healthcare Capital Partners LLC	5.49%	DEF14A
Entities affiliated with BlackRock, Inc.	5.29%	DEF14A
T. Rowe Price	5.21%	13F
Pfizer Inc.	5.20%	DEF14A
Vanguard Group	4.39%	13F

Percentages above are of 103,486,412 shares outstanding, as reported by ORIC Pharmaceuticals, Inc. on its Form 10-Q dated 2026-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from ORIC Pharmaceuticals, Inc.’s 10-Q dated 2026-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At ORIC Pharmaceuticals, Inc.'s shareholder meeting held 2026-06-18, in the 2025-2026 proxy season, 189 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,586 separate fund positions. Their filings are grouped here into 8 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. ORIC Pharmaceuticals, Inc.'s own Form 8-K tally for this meeting is published below, but no row in it could be matched to the most widely held item, so this page states no certified outcome for that item. On that item — TO APPROVE, ON AN ADVISORY BASIS, THE FREQUENCY OF FUTURE ADVISORY VOTES ON EXECUTIVE… — the reporting funds cast — of the shares they voted in favour (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). That is the aggregate of those managers' own N-PX disclosures, not the company's certified result, and the funds are a subset of all shareholders.

ORIC Pharmaceuticals, Inc. proxy season coverage: 2025-2026 (this page).